Revenue
$22.97B
Fiscal year ended 2026-06-30Operating income
Unavailable
Fiscal year ended 2026-06-30Free cash flow
Unavailable
Fiscal year ended 2026-06-30ELI LILLY & Co (LLY) reported revenue of $22.97B and net income of $7.10B for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ELI LILLY & Co’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B | $13.53B | $11.44B | $11.30B | $8.77B |
| Cost of revenue | $3.27B | $3.58B | $3.37B | $3.01B | $2.45B | $2.22B | $2.40B | $2.17B | $2.17B | $1.67B |
| Gross profit | $19.71B | $16.22B | $15.92B | $14.59B | $13.11B | $10.50B | $11.13B | $9.27B | $9.13B | $7.09B |
| Operating income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net income | $7.10B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B | $970.30M | $2.97B | $2.24B |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 893.70M | shares 895.90M | Unavailable | shares 898.80M | shares 899.80M | shares 900.60M | Unavailable | shares 905.00M | shares 904.20M | shares 903.80M |
| Pretax income | $9.25B | $8.85B | $8.27B | $7.23B | $6.78B | $3.46B | $5.04B | $1.59B | $3.52B | $2.54B |
| Income tax expense | $2.15B | $1.45B | $1.63B | $1.65B | $1.12B | $697.00M | $628.50M | $618.10M | $550.20M | $293.20M |
| Diluted EPS | $7.94 | $8.26 | Unavailable | $6.21 | $6.29 | $3.06 | Unavailable | $1.07 | $3.28 | $2.48 |
| Selling, general & administrative | $3.43B | $2.93B | $3.13B | $2.74B | $2.75B | $2.47B | $2.42B | $2.10B | $2.12B | $1.95B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B | $3.27B | $3.37B | $3.22B | $2.46B |
| Total assets | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.72B | $75.61B | $71.87B | $63.94B |
| Current assets | $64.67B | $54.84B | $55.63B | $62.07B | $49.85B | $41.26B | $32.74B | $31.42B | $30.20B | $25.19B |
| Total liabilities | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current liabilities | $47.74B | $36.63B | $35.23B | $40.14B | $39.02B | $30.07B | $28.38B | $24.67B | $27.12B | $18.60B |
| Total equity incl. NCI | $33.88B | $31.20B | $26.54B | $23.85B | $18.35B | $15.85B | $14.27B | $14.32B | $13.64B | $12.90B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $16.79B | $14.53B | $13.74B | $12.18B | $11.01B | $9.31B | $7.59B | $7.46B | $6.48B | $6.10B |
| Accounts receivable | $20.08B | $18.43B | $17.76B | $16.11B | $14.17B | $12.04B | $11.01B | $10.29B | $11.03B | $7.89B |
| Goodwill | $8.85B | $6.13B | $5.90B | $5.90B | $5.77B | $5.77B | $5.77B | $5.77B | $5.77B | $4.94B |
| Long-term debt | $47.86B | $39.37B | $40.87B | $40.87B | $34.18B | $34.50B | $28.53B | $29.05B | $23.73B | $24.56B |
| Accounts payable | $6.11B | $5.03B | $5.38B | $4.26B | $4.08B | $3.44B | $3.23B | $2.89B | $2.92B | $2.47B |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.69B | $5.33B | $3.22B | $8.84B | $3.09B | $1.67B | $2.47B | $3.71B | $1.47B | $1.17B |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | -$15.40B | -$3.92B | -$2.80B | -$2.98B | -$1.83B | -$3.35B | -$1.92B | -$4.00B | -$2.20B | -$1.18B |
| Financing cash flow | $8.43B | -$3.47B | -$2.88B | $530.80M | -$1.24B | $1.38B | -$225.50M | $211.30M | $1.56B | -$311.30M |
| Net change in cash | $3.67B | -$1.99B | -$2.52B | $6.42B | $283.00M | -$175.00M | -$101.40M | $145.40M | $763.40M | -$358.40M |
| Stock-based compensation | $201.00M | $161.00M | $136.10M | $150.90M | $185.00M | $154.00M | $142.30M | $133.20M | $211.10M | $159.40M |
| Common dividends paid | $1.55B | $1.55B | $1.35B | $1.35B | $1.35B | $1.35B | $1.17B | $1.17B | $1.17B | $1.17B |
| Common share repurchases | $1.60B | $2.36B | $1.51B | $708.30M | $692.00M | $1.20B | $2.05B | $446.10M | $0 | $0 |
| Depreciation & amortization | $534.00M | $509.00M | $585.70M | $470.30M | $478.00M | $463.00M | $485.20M | $466.80M | $414.40M | $400.60M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | 85.8% | 81.9% | 82.5% | 82.9% | 84.3% | 82.5% | 82.2% | 81.0% | 80.8% | 80.9% |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 0.9% | 0.8% | 0.7% | 0.9% | 1.2% | 1.2% | 1.1% | 1.2% | 1.9% | 1.8% |
| Current ratio | 1.35x | 1.50x | 1.58x | 1.55x | 1.28x | 1.37x | 1.15x | 1.27x | 1.11x | 1.35x |
| Revenue YoY growth | 47.7% | 55.5% | 42.6% | 53.9% | 37.6% | 45.2% | 44.7% | 20.4% | 36.0% | 26.0% |
| Net margin | 30.9% | 37.4% | 34.4% | 31.7% | 36.4% | 21.7% | 32.6% | 8.5% | 26.3% | 25.6% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | 1.41x | 1.26x | 1.54x | 1.71x | 1.86x | 2.18x | 2.00x | 2.03x | 1.74x | 1.90x |
| Effective tax rate | 23.3% | 16.4% | 19.7% | 22.8% | 16.5% | 20.2% | 12.5% | 38.9% | 15.6% | 11.6% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LLY in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.